JP2008529532A5 - - Google Patents

Download PDF

Info

Publication number
JP2008529532A5
JP2008529532A5 JP2007555320A JP2007555320A JP2008529532A5 JP 2008529532 A5 JP2008529532 A5 JP 2008529532A5 JP 2007555320 A JP2007555320 A JP 2007555320A JP 2007555320 A JP2007555320 A JP 2007555320A JP 2008529532 A5 JP2008529532 A5 JP 2008529532A5
Authority
JP
Japan
Prior art keywords
egfr
gefitinib
erlotinib
cancer
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007555320A
Other languages
English (en)
Japanese (ja)
Other versions
JP4898710B2 (ja
JP2008529532A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/005050 external-priority patent/WO2006086777A2/en
Publication of JP2008529532A publication Critical patent/JP2008529532A/ja
Publication of JP2008529532A5 publication Critical patent/JP2008529532A5/ja
Application granted granted Critical
Publication of JP4898710B2 publication Critical patent/JP4898710B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2007555320A 2005-02-11 2006-02-13 薬剤耐性egfr突然変異体を検出するための方法および組成物 Active JP4898710B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65248805P 2005-02-11 2005-02-11
US60/652,488 2005-02-11
PCT/US2006/005050 WO2006086777A2 (en) 2005-02-11 2006-02-13 Methods and compositions for detecting a drug resistant egfr mutant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011250657A Division JP2012070746A (ja) 2005-02-11 2011-11-16 薬剤耐性egfr突然変異体を検出するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2008529532A JP2008529532A (ja) 2008-08-07
JP2008529532A5 true JP2008529532A5 (enExample) 2011-01-13
JP4898710B2 JP4898710B2 (ja) 2012-03-21

Family

ID=36793833

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007555320A Active JP4898710B2 (ja) 2005-02-11 2006-02-13 薬剤耐性egfr突然変異体を検出するための方法および組成物
JP2011250657A Pending JP2012070746A (ja) 2005-02-11 2011-11-16 薬剤耐性egfr突然変異体を検出するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011250657A Pending JP2012070746A (ja) 2005-02-11 2011-11-16 薬剤耐性egfr突然変異体を検出するための方法および組成物

Country Status (7)

Country Link
US (2) US8067175B2 (enExample)
EP (2) EP1851339B1 (enExample)
JP (2) JP4898710B2 (enExample)
CN (1) CN101193905B (enExample)
CA (1) CA2597673C (enExample)
ES (1) ES2586410T3 (enExample)
WO (1) WO2006086777A2 (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006086777A2 (en) * 2005-02-11 2006-08-17 Memorial Sloan Kettering Cancer Center Methods and compositions for detecting a drug resistant egfr mutant
US12366585B2 (en) 2006-05-18 2025-07-22 Caris Mpi, Inc. Molecular profiling of tumors
AU2009246398A1 (en) 2008-05-14 2009-11-19 Bristol-Myers Squibb Company Predictors of patient response to treatment with EGF receptor inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP2361248B1 (en) 2008-06-27 2018-09-19 Celgene CAR LLC Heteroaryl compounds and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US9089844B2 (en) 2010-11-01 2015-07-28 Bio-Rad Laboratories, Inc. System for forming emulsions
US8633015B2 (en) 2008-09-23 2014-01-21 Bio-Rad Laboratories, Inc. Flow-based thermocycling system with thermoelectric cooler
US9156010B2 (en) 2008-09-23 2015-10-13 Bio-Rad Laboratories, Inc. Droplet-based assay system
US8709762B2 (en) 2010-03-02 2014-04-29 Bio-Rad Laboratories, Inc. System for hot-start amplification via a multiple emulsion
US9132394B2 (en) 2008-09-23 2015-09-15 Bio-Rad Laboratories, Inc. System for detection of spaced droplets
US9598725B2 (en) 2010-03-02 2017-03-21 Bio-Rad Laboratories, Inc. Emulsion chemistry for encapsulated droplets
US12162008B2 (en) 2008-09-23 2024-12-10 Bio-Rad Laboratories, Inc. Partition-based method of analysis
US12090480B2 (en) 2008-09-23 2024-09-17 Bio-Rad Laboratories, Inc. Partition-based method of analysis
US9399215B2 (en) 2012-04-13 2016-07-26 Bio-Rad Laboratories, Inc. Sample holder with a well having a wicking promoter
US11130128B2 (en) 2008-09-23 2021-09-28 Bio-Rad Laboratories, Inc. Detection method for a target nucleic acid
US9492797B2 (en) 2008-09-23 2016-11-15 Bio-Rad Laboratories, Inc. System for detection of spaced droplets
US10512910B2 (en) 2008-09-23 2019-12-24 Bio-Rad Laboratories, Inc. Droplet-based analysis method
CN102405402A (zh) 2008-09-23 2012-04-04 阔达生命有限公司 基于液滴的测定系统
US9417190B2 (en) 2008-09-23 2016-08-16 Bio-Rad Laboratories, Inc. Calibrations and controls for droplet-based assays
US9764322B2 (en) 2008-09-23 2017-09-19 Bio-Rad Laboratories, Inc. System for generating droplets with pressure monitoring
WO2011120024A1 (en) 2010-03-25 2011-09-29 Quantalife, Inc. Droplet generation for droplet-based assays
WO2011120006A1 (en) 2010-03-25 2011-09-29 Auantalife, Inc. A Delaware Corporation Detection system for droplet-based assays
US8951939B2 (en) 2011-07-12 2015-02-10 Bio-Rad Laboratories, Inc. Digital assays with multiplexed detection of two or more targets in the same optical channel
CN101463390B (zh) * 2008-12-31 2011-09-14 广州益善生物技术有限公司 Egfr基因外显子20突变的检测探针、液相芯片及其检测方法
EP3722810A3 (en) * 2009-02-11 2021-01-13 Caris MPI, Inc. Molecular profiling of tumors
CN101608240B (zh) * 2009-04-13 2011-06-29 郑立谋 用于检测人类egfr基因突变的引物、探针及其使用方法
JP5918693B2 (ja) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Egfr阻害剤及び疾患の治療方法
CA3021714C (en) 2009-09-02 2021-03-09 Bio-Rad Laboratories, Inc. System for mixing fluids by coalescence of multiple emulsions
CN102021232A (zh) * 2009-09-22 2011-04-20 北京雅康博生物科技有限公司 用于定量检测egfr突变的试剂盒
KR101472940B1 (ko) 2009-10-30 2014-12-24 아크레이 가부시키가이샤 Egfr 유전자 다형 검출용 프로브 및 그 용도
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
EP2542692B1 (en) 2010-03-04 2016-08-24 Carpén, Olli Method for selecting patients for treatment with an egfr inhibitor
EP2556170A4 (en) 2010-03-25 2014-01-01 Quantalife Inc TRAPPING TRANSPORT AND DETECTION SYSTEM
CN102234683B (zh) * 2010-04-23 2013-07-17 广州益善生物技术有限公司 一种egfr基因突变检测液相芯片
NZ607845A (en) 2010-08-10 2015-03-27 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
US9315848B2 (en) 2010-08-18 2016-04-19 Technion Research And Development Foundation Ltd. Volatile organic compounds for detecting cell dysplasia and genetic alterations associated with lung cancer
JP5860667B2 (ja) 2010-10-29 2016-02-16 アークレイ株式会社 Egfrエクソン21l858r遺伝子多型検出用プライマーセット及びその用途
EP2635285B1 (en) 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2012061299A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
US8796255B2 (en) 2010-11-10 2014-08-05 Celgene Avilomics Research, Inc Mutant-selective EGFR inhibitors and uses thereof
EP2468883A1 (en) * 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US12097495B2 (en) 2011-02-18 2024-09-24 Bio-Rad Laboratories, Inc. Methods and compositions for detecting genetic material
CN103534360A (zh) 2011-03-18 2014-01-22 伯乐生命医学产品有限公司 借助对信号的组合使用进行的多重数字分析
AU2012249759A1 (en) 2011-04-25 2013-11-07 Bio-Rad Laboratories, Inc. Methods and compositions for nucleic acid analysis
EP2737089B1 (en) 2011-07-29 2017-09-06 Bio-rad Laboratories, Inc. Library characterization by digital assay
EP2770830A4 (en) 2011-10-28 2015-05-27 Celgene Avilomics Res Inc METHODS OF TREATING A DISEASE OR DISEASE ASSOCIATED WITH TYROSINE KINASE BTK (BRUTON'S TYROSINE KINASE)
CN103184274A (zh) * 2011-12-27 2013-07-03 上海复星医学科技发展有限公司 一种ldr技术的egfr突变检测试剂盒
MX356753B (es) 2012-03-15 2018-06-12 Celgene Avilomics Res Inc Formas solidas de un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
PT2825042T (pt) 2012-03-15 2018-11-16 Celgene Car Llc Sais de um inibidor de cinases do recetor do fator de crescimento epidérmico
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2014124230A2 (en) 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Erk inhibitors and uses thereof
US20140287417A1 (en) 2013-03-08 2014-09-25 Roche Molecular Systems, Inc. EGFR Blood Monitoring
EP2964781B1 (en) 2013-03-08 2018-01-10 Roche Diagnostics GmbH Egfr mutation blood testing
WO2014147631A1 (en) 2013-03-22 2014-09-25 Natco Pharma Limited Formulation comprising gefitinib as oral suspension
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
GB201402996D0 (en) * 2014-02-20 2014-04-09 Vela Operations Pte Ltd Variant analysis in high-throughput sequencing applications
WO2015187855A1 (en) * 2014-06-03 2015-12-10 The Regents Of The University Of California Non-invasive gene mutation detection in lung cancer patients
ES2741785T3 (es) 2014-08-13 2020-02-12 Celgene Car Llc Formas y composiciones de un inhibidor de ERK
CN106498028B (zh) * 2016-05-26 2020-06-30 格诺思博生物科技南通有限公司 Egfr的t790m突变的诊断方法及试剂盒
SG11201810694WA (en) * 2016-06-03 2018-12-28 Singapore Health Serv Pte Ltd Use of biomarkers in determining susceptibility to disease treatment
CN106498029B (zh) * 2016-06-20 2020-05-19 格诺思博生物科技南通有限公司 提高egfr的t790m突变的诊断效率的方法
JP2018088883A (ja) * 2016-12-06 2018-06-14 東洋紡株式会社 上皮成長因子受容体遺伝子変異の検出方法
CN106811522A (zh) * 2016-12-26 2017-06-09 北京奥维森基因科技有限公司 用于检测以egfp为靶点的药物相关基因耐药位点的pcr引物组及其应用和检测试剂盒
US9980967B1 (en) 2017-03-16 2018-05-29 National Chiao Tung University Method for overcoming drug resistance of EGFR mutation and cancerous stemness of human non-small cell lung carcinoma
CN106906295B (zh) * 2017-03-31 2020-12-08 天津诺禾致源生物信息科技有限公司 数字pcr检测基因点突变方法及装置
CN108546748A (zh) * 2017-04-05 2018-09-18 杭州丹威生物科技有限公司 一种检测核酸的方法和试剂盒
CN109722478A (zh) * 2017-10-31 2019-05-07 嘉兴雅康博医学检验所有限公司 用于检测egfr基因2312-2313位突变的引物、探针及试剂盒
WO2019176939A1 (ja) 2018-03-15 2019-09-19 栄研化学株式会社 一塩基多型検出用オリゴヌクレオチドプローブ、及びシス型-トランス型判別方法
US11459391B2 (en) 2019-02-26 2022-10-04 Janssen Biotech, Inc. Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies
CN111748026A (zh) * 2019-03-29 2020-10-09 天津亨佳生物科技发展有限公司 一种针对egfr l858r基因突变的特异性t细胞受体及其应用
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
KR20230039608A (ko) * 2020-05-07 2023-03-21 더 리전츠 오브 더 유니버시티 오브 캘리포니아 혈장 및 타액의 액체 생검 플랫폼

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4182124A (en) 1977-01-28 1980-01-08 Kraus Edmund J Gravity augmented air compression turbine power plant
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
CA1142466A (en) 1979-01-09 1983-03-08 Cesar Milstein Cell lines
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US5030565A (en) 1983-08-17 1991-07-09 Scripps Clinic And Research Foundation Polypeptide-induced monoclonal receptors to protein ligands
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5561058A (en) 1986-08-22 1996-10-01 Hoffmann-La Roche Inc. Methods for coupled high temperatures reverse transcription and polymerase chain reactions
CA1339731C (en) 1988-10-12 1998-03-17 Charles T. Caskey Multiplex genomic dna amplification for deletion detection
US5223168A (en) 1989-12-12 1993-06-29 Gary Holt Surface cleaner and treatment
US5506351A (en) 1992-07-23 1996-04-09 Isis Pharmaceuticals Process for the preparation of 2'-O-alkyl guanosine and related compounds
US5212295A (en) 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
DE69131255T2 (de) 1990-01-26 1999-12-16 Washington Research Foundation, Seattle Immunreaktivität gegenüber exprimierten aktivierten Oncogenen zur Diagnose und Behandlung von bösartigen Geschwülsten
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US6262241B1 (en) 1990-08-13 2001-07-17 Isis Pharmaceuticals, Inc. Compound for detecting and modulating RNA activity and gene expression
US5852184A (en) 1990-11-28 1998-12-22 Ludwig Institute For Cancer Research Protein tyrosine kinase
US5610276A (en) 1991-05-17 1997-03-11 Chiron Corporation Polypeptides and antibodies derived from GAP associated protein, p62
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5599797A (en) 1991-10-15 1997-02-04 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5633134A (en) 1992-10-06 1997-05-27 Ig Laboratories, Inc. Method for simultaneously detecting multiple mutations in a DNA sample
US5405941A (en) 1993-04-15 1995-04-11 National Jewish Center For Immunology And Respiratory Medicine MEKK protein, capable of phosphorylating MEK
US5571902A (en) 1993-07-29 1996-11-05 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
US5554746A (en) 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids
US5589330A (en) 1994-07-28 1996-12-31 Genzyme Corporation High-throughput screening method for sequence or genetic alterations in nucleic acids using elution and sequencing of complementary oligonucleotides
US5939269A (en) 1994-12-28 1999-08-17 The Regents Of The University Of California Antagonists to insulin receptor tyrosine kinase inhibitor
US6066625A (en) 1998-02-03 2000-05-23 Methylgene, Inc. Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences
US6503754B1 (en) 2000-09-07 2003-01-07 Isis Pharmaceuticals, Inc. Antisense modulation of BH3 interacting domain death agonist expression
EP2186901B1 (en) 2001-06-14 2015-06-03 The Regents of The University of California Mutations in the BCR-Abl-tyrosine kinase associated with resistance to STI-571
EP2439285B1 (en) 2004-03-31 2019-05-08 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
EP2592155B2 (en) 2004-06-04 2019-09-11 Genentech, Inc. EGFR mutations
RU2405566C9 (ru) 2005-02-03 2012-04-27 Дзе Дженерал Хоспитал Корпорейшн Способ лечения рака, устойчивого к гефитинибу
WO2006086777A2 (en) * 2005-02-11 2006-08-17 Memorial Sloan Kettering Cancer Center Methods and compositions for detecting a drug resistant egfr mutant
KR20070106029A (ko) 2005-02-24 2007-10-31 암젠 인코포레이티드 상피세포 성장 인자 수용체 돌연변이
EP1881079A1 (en) 2006-07-20 2008-01-23 Pangaea Biotech, S.A. Method for the detection of EGFR mutations in blood samples

Similar Documents

Publication Publication Date Title
JP2008529532A5 (enExample)
Sakuma et al. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations
Nowak et al. Detection of mismatch repair deficiency and microsatellite instability in colorectal adenocarcinoma by targeted next-generation sequencing
Kimura et al. High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non‐small cell lung cancer patients
CN103255201B (zh) 一种基于Blocker引物和ARMS引物检测基因突变的方法和试剂盒
Huang et al. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment
JP2009077712A5 (enExample)
JP2010051316A5 (enExample)
CN103382503B (zh) Egfr基因19号外显子19种缺失突变检测试剂盒及检测方法
JP2008509673A5 (enExample)
CN102985562A (zh) 鉴别多态性乙肝病毒和kras致癌基因突变及其临床应用
WO2017075784A1 (zh) 肺腺癌生物标记物及其应用
CN106048008A (zh) 一种egfr基因超低频突变检测试剂盒
JP2023505031A (ja) がんの分析のための方法及び組成物
US20220162710A1 (en) Composition for diagnosis or prognosis prediction of glioma, and method for providing information related thereto
Yoon et al. Peptide nucleic acid clamping versus direct sequencing for the detection of EGFR gene mutation in patients with non-small cell lung cancer
Ibrahem et al. Comparative analysis of pyrosequencing and QMC‐PCR in conjunction with high resolution melting for KRAS/BRAF mutation detection
Wang et al. Screening and application of inhibitory aptamers for DNA repair protein apurinic/apyrimidinic endonuclease 1
CN103103284A (zh) 一种用于定量检测ikzf1基因突变的试剂盒
WO2009087689A4 (en) Novel primers for identification of astrocytoma, it's grades and glioblastoma prognosis
EP2788505A2 (en) Methods of detecting mutations and epigenetic changes
JP6153758B2 (ja) 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用キット
Sahnane et al. Pyrosequencing for EGFR mutation detection: diagnostic accuracy and clinical implications
CN109593856A (zh) 一种检测kras基因外显子2密码子12/13突变的试剂盒及其制备方法
WO2012049279A1 (en) MEANS AND METHODS APPLYING SINGLE NUCLEOTIDE PRIMER EXTENSION WITH ION PAIR-, REVERSED-PHASE HPLC (SIRPH) FOR THE DIAGNOSIS OF SNPs